Retraction of “Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin”

Andrew S. Goldsborough, Misty D. Handley, Andres E. Dulcey, Kristen M. Pluchino, Pavitra Kannan, Kyle R. Brimacombe, Matthew D. Hall, Gary Griffiths, and Michael M. Gottesman*

J. Med. Chem. 2011, 54 (14), 4987−4997, DOI: 10.1021/jm2001663

The authors retract this Article. While the data are correct and reproducible, postpublication research revealed mycoplasma contamination of the cell lines under investigation. In a separate Article, published simultaneously with this Retraction (“Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale”, J. Med. Chem., DOI: 10.1021/acs.jmedchem.9b00484), we demonstrate that the hypersensitivity of multidrug-resistant cell lines to tiopronin is the result of mycoplasma infection. While the phenotype reported (hypersensitivity of mycoplasma-infected multidrug-resistant cancer cells to tiopronin compared to mycoplasma-infected parental cells) and data are accurate, we are retracting this Article and publishing the explanation to correct the scientific record.

The original Article was published on June 9, 2011, and retracted on February 4, 2020.

ASSOCIATED CONTENT

Related Articles
A new Brief Article has been published (J. Med. Chem. 2020, DOI: 10.1021/acs.jmedchem.9b00484).

Published: February 4, 2020